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and assumptions were based on the NICE/External Assessment Centre report and 
published literature when possible. Results: Adoption of Sherlock 3CG® TCS was 
predicted to be more or less cost neutral per patient when compared with “blind” 
bedside in both the U.K. (£9.37) and the U.S. ($18.73). Further, Sherlock 3CG® TCS 
was predicted to be cost-saving per patient compared with fluoroscopy in the U.K. 
(-£106.12) or compared with a TLS in the U.S. (-$18.43). These results were robust 
to the majority of sensitivity analyses. ConClusions: This study predicts that 
Sherlock 3CG® TCS is an economically favorable strategy from both U.K. and U.S. 
perspectives and can provide additional patient and healthcare worker benefits. 
Additional analyses in other regions may help to further substantiate these results.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Germany. Methods: An economic model quantified 30-day 
cost impact of EVARREST® from a German hospital perspective. Severe soft tis-
sue bleeding trial resources included quantity of initial treatment, re-treatment, 
surgery time, transfusion risk, amount transfused, and hospitalization (including 
ICU and ward stay). SoC was composed of Surgicel® (88%) and conventional meth-
ods (e.g., manual compression). The surgical analysis included resources clinically 
related to the significant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and 
re-treatment, operating time, transfusion). A hospital analysis included all resources 
collected. Published data on German costs were applied to resource use. A sub-
group analysis was conducted for patients meeting coagulopathic criteria based 
on abnormal values for at least one of the trial coagulation parameters collected. 
Value-added tax (19%) was added to product costs. Results: The surgical base-case 
analysis predicted that EVARREST® cost was offset by averted resource use with per 
patient cost impact of € 1,893 vs. SoC. The hospital analysis predicts further resource 
reduction with EVARREST® leading to cost impact of € 608 per patient. In coagulo-
pathic patients, the results dramatically improved, with the surgical and hospital 
analysis both showing cost-savings of € 542 and € 3,275 with EVARREST®vs. SoC 
respectively. ConClusions: In problematic bleeding situations, EVARREST® may 
result in important cost savings for hospitals, in addition to meeting an important 
unmet need. This analysis suggests results may depend on surgical bleeding type, 
with increased benefit seen in challenging (i.e., coagulopathic) bleeding patients. 
Further study is needed to confirm findings.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Italy. Methods: An economic model quantified 30-day cost 
impact of EVARREST® from an Italian hospital perspective. Severe soft tissue bleed-
ing trial resources included quantity of initial treatment, re-treatment, surgery time, 
transfusion risk, amount transfused, and hospitalization (including ICU and ward 
stay). SoC was composed of Surgicel® (88%) and conventional methods (e.g., manual 
compression). The surgical analysis included resources clinically related to the sig-
nificant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and re-treatment, 
operating time, transfusion). A hospital analysis included all resources collected. 
Published data on Italian costs were applied to resource use. A subgroup analysis 
was conducted for patients meeting coagulopathic criteria based on abnormal val-
ues for at least one of the trial coagulation parameters collected. Results: The 
surgical base-case analysis predicted that EVARREST® cost was offset by averted 
resource use with per patient cost impact of € 1,016 vs. SoC. The hospital analysis 
predicts further resource reduction with EVARREST® leading to cost-savings of € 708 
per patient. In coagulopathic patients, the results dramatically improved, with the 
surgical and hospital analysis both showing cost-savings of € 2,366 and € 6,128, with 
EVARREST®vs. SoC respectively. ConClusions: In problematic bleeding situations, 
EVARREST® may result in important cost savings for hospitals, in addition to meet-
ing an important unmet need. This analysis suggests results may depend on surgi-
cal bleeding type, with increased benefit seen in challenging (i.e., coagulopathic) 
bleeding patients. Further study is needed to confirm findings.
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objeCtives: economic analysis of telemedical technologies application for regular 
medical examination among the adult population living far from hospitals in the 
PMD139
using rEAl-WorlD hosPitAl PurchAsing AnD consuMPtion DAtA to 
iMProvE hEAlthcArE systEMs EfficiEnciEs
Carlow D, Dua D, Erickson G, Garfield S
GfK Custom Research, Wayland, MA, USA
objeCtives: Presently, there is a disparity between the purchasing power of vari-
ous hospital institutions within Germany. Large institutions, those within hospital 
networks, and those with group purchasing organization (GPO) memberships can 
leverage their influence to secure favorable prices for medical devices and consuma-
bles. Other institutions, however, are not able to leverage the same purchasing power, 
resulting in higher prices and financial inefficiencies. The objective of this work was 
to measure the financial impact to a broad spectrum of hospitals using real-world 
German hospital purchasing and consumption data. Methods: GfK Hospital Panel, a 
proprietary database for German hospital medical devices and consumables purchas-
ing and consumption was evaluated. Wound care purchasing data was evaluated to 
see similarities and differences in purchasing volume, acquisition cost, and product 
utilization. Products used to promote infection control and healing in post-surgical 
sites were prioritized. Results: The hospital purchasing and consumption data 
identified how specific products were used within and across hospitals. Differences 
in consumption by specialty department/units show how purchasing decisions are 
being concentrated in different settings. Hospitals with greater buying power and 
those with access to group purchasing organizations paid less per unit price than 
other hospitals, however the mix of products used varied by setting. Advanced wound 
care products had the greatest variability in usage among hospitals within the sam-
ple. ConClusions: Databases that provide detailed hospital purchasing data provide 
greater transparency to both hospitals and innovators on purchasing, pricing, and 
utilization trends. Smaller hospitals and those independently negotiating purchasing 
contracts can leverage this information to understand practice in other hospital set-
tings as they make decisions for their own. These data are likely to have a significant 
impact in rationalizing expenditures across the German Healthcare System, providing 
transparency to help hospitals make better purchasing decisions.
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objeCtives: Intraoperative watertight dural closure is critical as CSF leakage can 
lead to an increased risk of costly clinical consequences (e.g., wound infection, men-
ingitis). Although there are several fibrin sealants available, not all are indicated 
for sealing dura mater. An economic analysis compared a fibrin sealant (EVICEL® 
Solutions for Sealant) with standard of care (SoC) for sutured dural closure in cranial 
surgery in the United Kingdom (UK). Methods: The economic analysis quantified 
the 30-day cost impact of EVICEL® from a U.K. hospital perspective based on a surgical 
approach using clinical trial data. SoC was composed of sutures in addition to rescue 
therapy for the majority of the population. Trial-reported resources used included 
the quantity of initial treatment, adjunctive and rescue therapy product utilization, 
operating room (OR) time, hospitalization duration, and risk of dural-related adverse 
events. Only SoC treatment successes were allowed to receive additional adjunctive 
therapies to ensure durability of closure; however, treatment failures in both Evicel® 
and SoC could receive rescue therapies. Adjunctive therapies consisted of sutures, 
collagen, and haemostats (not fibrin sealants); where as rescue therapies consisted 
of various glues, haemostats and autologous dural patches. Published data on U.K. 
costs were applied to resource use and several one-way sensitivity analyses were 
conducted. Results: The analysis estimated that resource savings with EVICEL® 
completely offset its acquisition cost and resulted in cost savings of £207 per patient 
(sensitivity range: -£727.02 to £313.40) compared with SoC. Results remained robust 
to the majority of sensitivity analyses; however were most sensitive to assumptions 
regarding OR time and hospitalization duration. ConClusions: The use of EVICEL® 
for suture line dural closure may result in important cost savings for hospitals, partly 
driven by the reduced need for other adjunctive and rescue therapies. Further studies 
in larger populations may help to substantiate findings.
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objeCtives: The Sherlock 3CG® Tip Confirmation System (TCS) is designed to con-
firm the correct tip placement of a peripherally inserted central catheter (PICC) by 
using magnetic real-time tracking and electrocardiographic catheter tip confirma-
tion. The National Institute for Health and Care Excellence (NICE) recommended 
the adoption of Sherlock 3CG® TCS based on modelled health economic benefits 
in the United Kingdom (U.K.). The objective of this study was to develop a United 
States (U.S.) model for Sherlock 3CG® TCS and compare these results to the U.K. 
analyses. Methods: Sherlock 3CG® TCS was compared with “blind” beside PICC 
placement, as well as region-specific PICC placement methods (i.e., fluoroscopy in 
the U.K. and tip location system (TLS) in the U.S.). Clinical and economic outcomes 
were assessed per patient over the duration of a successful PICC insertion procedure. 
All eligible patients with an identifiable P-wave in their ECG rhythm were assumed 
to switch to Sherlock 3CG® TCS and did not require confirmatory chest x-rays. PICC 
placement success rates, as well as region-specific costs for capital, maintenance, 
nurse training, consumable materials, and chest x-rays were included. Parameters 
A370  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
objeCtives: As different inhalation devices require largely different techniques 
of use, the non-trained switch of device in chronic obstructive pulmonary disease 
(COPD) and asthma patients may be associated with a poor inhalation technique 
and, consequently, in a reduction of adherence and worsening in pathology con-
trol. Aim of this analysis is to estimate the possible economic impact on Italian 
National Health Service (INHS) related to errors in inhalation in patients switching 
device without adequate training. Methods: An Italian observational study on 
patients with COPD and asthma, highlights higher healthcare resource consump-
tion associated with inhaler mishandling. Particularly, significantly higher rates of 
hospitalizations, emergency room (ER) access and pharmacological treatment (ster-
oids and antimicrobials) were observed. These differences in resource consumption 
were monetized from the INHS perspective considering national DRGs tariffs for 
hospitalizations and ER access and public price for drugs consumption. Results: 
Comparing a population of 100 COPD patients with at least a critical error in inha-
lation with 100 COPD patients without errors in inhalation, the first population 
is associated with an excess of 11.5 hospitalizations, 13 ER access, 19.5 antimi-
crobial courses and 47 corticosteroids courses. In the same way, if we compare 
100 asthma patients with at least a critical error in inhalation with 100 asthma 
patients without errors in inhalation, the first population is associated with an 
excess of 19 hospitalizations, 26.5 ER access, 4.5 antimicrobial courses and 21.5 
corticosteroids courses. These differences in resource consumption are associated 
with an yearly incremental cost for 100 patients, due to inhalation errors, of 23,444€ 
in COPD patients and 44,104€ in asthma. ConClusions: This evaluation shows 
that misuse of inhalation devices, possibly associated to inadequate training or 
non-consented switch of inhaled medications, is associated with a decrease in 
disease control and an increase in healthcare resource consumption and costs in 
COPD and asthma patients.
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objeCtives: Objective of this study is to elaborate on the Turkish medical devices 
(MDs) reimbursement system. Methods: Health Implementation Communiqué 
(SUT), MD Reimbursement Guidelines and National Data Bank of Medicines and 
MDs (TITUBB) are analyzed. Results: Ministry of Health (MoH) is responsible 
for medicines’ and MDs’ registration, while Social Security Institution (SSI) is the 
payer and the decision-maker for reimbursement rules; defined by SUT. Holding 
CE-mark and MoH approval are prerequisites for reimbursement. All MDs are sub-
ject to generic listing: there are specialty-based positive lists, consisting of generic 
definitions and codes with corresponding ceiling reimbursement prices set by SSI. 
For inclusion into the positive lists, the manufacturer/distributor has to submit a 
“reimbursement dossier” to SSI. According to the “Application Guideline” published 
in May 2014, the content and level of evidence requirements for dossiers depend on 
the application type: For a new code or a new title creation, health-economics and 
clinical evidence are required. For matching to an existing code and applying for 
minor technical changes like barcode and label name of a product basic clinical data 
and MoH approval is sufficient. However C and D type are not processed currently 
due to existing TITUBB, joint data bank of MoH and SSI, allowing manufacturers 
to match products to existing SUT codes manually. A new system is planned to 
be launched which will not allow manual reimbursement approval and all code-
matchings will be evaluated by SSI with respect to above-mentioned Guideline. 
As neither the timeline for new system activation nor the evaluation criteria of 
dossiers are clearly determined, reimbursement evaluation processes are not fully-
transparent and predictable. ConClusions: MD reimbursement decisions are lim-
ited to basic safety, efficacy and clinical evidence. Due to existing generic listing 
practice, quality- or brand-based differentiation in reimbursement is not applied 
and price-differentiation for innovative and high-quality products does not prevail.
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objeCtives: Reconstruction techniques after a mastectomy have improved greatly 
in recent years, with much more natural results. Even so, a third of women choose 
not to have reconstruction. They turn to breast forms medical devices (MDBF). MDBF 
are reimbursed from Health insurance funds, but for MDBF with higher functional 
properties, there is a presence of higher patient co-payment. Methods: The target 
of the work was to analyse the data from paid databases of Slovak authority National 
Center for Health Information that collects the outputs of provided health care. The 
data were focused on totally or partly reimbursed medical devices (MD) from public 
health insurance funds. The selected group was medical devices for people after 
mastectomy – Brest forms. The most recent data were from 1.1. 2009 - 31.12. 2013. 
It was used basic and advanced statistic processing by Microsoft Excel. RESULTS: 
Referring to the National Center for Health Information, in the observed period, the 
share of MDBF on total consumption of MD stagnated (MDBF/MD2009= 0.0039%; 
MDBF/MD2013= 0.0038%; Δ MDBF/MD2009-2013= -0.0001%). The total quantitative 
consumption MDBF increased (Δ 2009-2013= 458pcs/14.16%; max2013= 4 101pcs; 
min2009= 3 235pcs; AVG= 3 693pcs; Mean= 3 685pcs; SD= 333). The share of MDBF on 
total reimbursement of MD stagnated (MDBF/MD2009= 0.14%; MDBF/MD2013= 0.12%; 
Δ MDBF/MD2009-2013= -0.02%). The total reimbursement in the observed period 
increased (Δ 2009-2013= 12 174€ /6.93%; max2013= 187 736€ ; min2009= 175 562€ ; 
AVG= 179 050€ ; Mean= 179 554€ ; SD= 5 651). The share of MDBF on the patient sup-
plements of MD stagnated (MDBF/MD2009= 0.27%; MDBF/MD2013= 0.23%; Δ MDBF/
MD2009-2013= -0.04%). The total patient supplements increased (Δ 2009-2013= 3 
700€ /43.36%; max2013= 12 234€ ; min2009= 8 534€ ; AVG= 11 637€ ; Mean= 12 234€ ; 
SD= 1 835). CONCLUSIONS: Development of MDBF costs is almost stable. MDBF has 
a higher patient co-payment. This fact is due to the current legislation when more 
Khanty-Mansi Autonomous Okrug – Yugra. Methods: The study consisted of three 
steps: 1. Analysis of the population structure in the study region with selection of 
patients group who can not pass medical examinations in hospitals. 2. Determination 
of equipment needed for the1st stage clinical examination for entire region popula-
tion. 3. Development of economic model to evaluate implementation of telemedical 
technologies for regular medical examination among the adult population living far 
from hospitals. The decision tree model compared two strategies for the clinical exam-
ination of patients: 1) with telemedicine complex, when physicians come to patient 
and 2) without telemedicine complex, when patient have to visit hospitals them-
selves. Sensitivity analysis was performed to analyze changes in the results when 
the duration of use of telemedicine equipment (time horizon) was varied. Results: 
One-time costs of telemedicine complex was € 1,44 million. The amount of spend-
ing for the telemedicine complex strategy was € 65,08 million for 3 years. The cost 
of strategy without telemedicine complex was € 62,27 million for the same time 
period. The difference between strategies amounted € 4,24 million. Investments in 
the acquisition of telemedicine complex are payed off in 1.02 years. ConClusions: 
Application of the telemedical complexallows to compensate acquisition costs in less 
than one and a half years and improves access to medical care for handicapped and 
remoted population of Khanty-Mansi Autonomous Okrug – Yugra.
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objeCtives: The German healthcare system was among the first markets to intro-
duce transcatheter aortic valve replacement (TAVR) in routine care. Our objective 
was to estimate the impact of TAVR availability on overall aortic valve replacement 
volumes and competing therapies in this real-world setting. Methods: Therapy- and 
age-specific procedure volumes were collected from German Federal Statistics Office 
databases for TAVR and surgical aortic valve replacement (SAVR) via sternotomy for 
years 2009 through 2013. Discharge and hospital-based mortality data were obtained 
for the same period based on applicable ICD-10 diagnosis. We computed therapy-
specific and total procedure volumes and growth stratified by 5-year age increments 
and in total. Discharge and mortality data for aortic valve disease hospitalizations was 
assessed to obtain an estimate of changes in per-case mortality. Results: In the time 
period 2009 to 2013 overall procedure volumes grew from 26,466 to 33,235 (+26%). This 
growth was driven by TAVR (3,411 to 10,814; +217%), while SAVR volumes remained 
stable (23,055 to 22,421; -3%). In patients 75 years or older, an overall procedure growth 
of 51% was observed (12,168 to 18,318), with volumes in older patient segments grow-
ing more heavily (+62% in > 80-year olds; +101% in > 85-year olds). Across all elderly 
age groups, SAVR volumes decreased (-20% in > 80 year olds; -37% in > 85 year olds), 
while they grew in selected younger patients groups (highest growth +30% in age 
group 60-64 yrs.). Concurrently, total aortic valve disease hospital discharges grew 
by 26%, from 44,161 to 55,748, while mortality per hospitalization case decreased by 
5% between 2009 and 2013. ConClusions: The availability of TAVR has contributed 
to substantial growth in aortic valve replacements in Germany, specifically in elderly 
populations previously left untreated. This growth was associated with a concurrent 
gradual decline in overall mortality of aortic valve-related hospitalizations.
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objeCtives: A recently published retrospective analysis of the US Premier database 
showed that in major spine surgeries (MSS; e.g., fusion/refusion 2-3 vertebrae), the 
hemostatic agent Floseal reduces operative room (OR) time by 8.84 min (p< 0.0001), 
transfusion rate by 0.2% (p< 0.0001) and product volume by 3.35 mL (p< 0.001) versus 
Surgiflo Thrombin. In severe spine surgeries (SSS, e.g. fusion/refusion 4+ vertebrae), 
Floseal reduces OR time by 26.94 min (p< 0.001) and product volume by 1.52 mL 
(p< 0.008) versus Surgiflo Thrombin. This analysis was undertaken to evaluate the 
cost-consequences of using Floseal versus Surgiflo Thrombin in spine procedures 
in 4 European countries. Methods: A cost-consequence model (hospital perspec-
tive) was built in Excel using the outcomes from the retrospective study: OR time, 
blood transfusion (assumption: 2 units per patient transfused) rates, product volume 
used. Unit costs were obtained for France, United Kingdom (UK), Germany and the 
Netherlands (NL) from official national sources or published literature. An annual 
case load of 1,000 MSS and 1,000 SSS per year was assumed. Monte-Carlo simulation 
was used to account for parameter uncertainty using the 95% confidence interval or 
± 20%. Results: Floseal could lead to net annual savings versus surgiflo thrombin 
ranging from 56,000€ (Germany) to 344,000€ (nl) for the 1,000 Mss case load and 
from 179,000€ (Germany) to 540,000€ (uK) for sss. Monte-Carlo simulations showed 
that savings are > 100€ per Mss and > 200€ per sss in 82 to 99% of iterations in 
uK and nl. that level of net savings is reached in a smaller number of iterations 
in other countries (e.g., 45-60% in France, 24-43% in Germany). ConClusions: 
This analysis indicates that using Floseal instead of Surgiflo Thrombin as adjunct to 
hemostasis in MSS and SSS could lead to sizable cost savings to hospitals, and that 
the importance of the savings is dependent on the country.
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